Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 19;16(4):e35357.
doi: 10.5812/hepatmon.35357. eCollection 2016 Apr.

Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B

Yue-Li Xiong  1 , Hu Li  1 , Fen Liu  1 , Dazhi Zhang  1 , Hong Ren  1 , Peng Hu  1
Affiliations

Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B

Yue-Li Xiong et al. Hepat Mon. .

Abstract

Background: After treatment cessation, a high prevalence of relapse was reported in chronic hepatitis B (CHB) patients in China, especially in nucleot(s)ide analogues (NUCs)-experienced patients. Re-treatment for these patients remains unsolved.

Objectives: This study aims to evaluate the efficacy of PEGylated interferon in HBeAg positive patients with exposure to antiviral therapy.

Patients and methods: A total of 55 treatment-experienced, HBeAg positive Chinese patients were enrolled in this study. Of these patients, 33 were NUCs-experienced and 22 were interferon-experienced. PEGylated interferon was administered to 34 patients; and 21 patients were retreated with conventional interferon.

Results: Of the 34 treatment-experienced patients who received PEGylated interferon, 52.9% achieved virologic response, and 41.2% achieved HBeAg loss and seroconversion. Patients who were treated with PEGylated interferon for 48 weeks achieved higher virologic response (80%); HBeAg loss (60%); HBeAg seroconversion (60%); and HBsAg loss (5%) than patients treated for 24 weeks with PEGylated interferon. Their responses were also higher than those who were treated with conventional interferon. HBeAg seroconversion in treatment-experienced patients was independently associated with 48-week PEGylated interferon therapy duration.

Conclusions: PEGylated interferon was effective in treatment-experienced patients with HBeAg positive CHB, and showed higher rates of virological response, HBeAg loss, and seroconversion. The results provide important information regarding the role of re-treatment with PEGylated interferon in treatment-experienced HBeAg positive patients.

Keywords: Chronic Hepatitis B; Nucleot(s)ide Analogues; PEGylated Interferon; Treatment-Experienced.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. A, Comparison of Response Rates of Retreatment With PegIFN for 48 Weeks and 24 Weeks; and B, Comparison of Response Rates of Retreatment With PegIFN for 48 Weeks and cIFN
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107. - PubMed
    1. European Association for the Study of the Liver EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85. doi: 10.1016/j.jhep.2012.02.010. - DOI - PubMed
    1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2. doi: 10.1002/hep.23190. - DOI - PubMed
    1. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6(3):531–61. doi: 10.1007/s12072-012-9365-4. - DOI - PubMed
    1. Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57(1):399–408. doi: 10.1002/hep.25937. - DOI - PubMed

LinkOut - more resources